Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity

被引：0
|
作者：
Phillips, A. L. [1 ]
Edwards, N. C. [2 ]
Locklear, J. C. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Hlth Serv Consulting Corp, Boxboro, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P839
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [41] COST-UTILITY ANA LYSIS OF INTRAMUSCULAR INTERFERON BETA-1B VERSUS SUBCUTANEOUS INTERFERON BETA-1B AND BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J.
    Delgado, A.
    VALUE IN HEALTH, 2016, 19 (03) : A63 - A63
  • [42] IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART® IN PATIENTS WITH MULTIPLE SCLEROSIS
    Edo-Solsona, M.
    Monte-Boquet, E.
    Casanova-Estruch, B.
    Poveda-Andres, J.
    VALUE IN HEALTH, 2016, 19 (07) : A435 - A435
  • [43] Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis
    Edo Solsona, Maria Dolores
    Monte Boquet, Emilio
    Casanova Estruch, Bonaventura
    Poveda Andres, Jose Luis
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 415 - 421
  • [44] Bioequivalence of two subcutaneous pharmaceutical products of interferon beta 1a
    Di Girolamo, Guillermo
    Kauffman, Marcelo A.
    Gonzalez, Eliseo
    Papouchado, Mariana
    Ramirez, Alejandra
    Keller, Guillermo
    Carbonetto, Cesar
    Dabsys, Susana
    Vidal, Alejandro
    Sterin-Prync, Aida
    Diez, Roberto A.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2008, 58 (04): : 193 - 198
  • [45] Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis
    Cristina Guijarro
    Julián Benito-León
    Félix Bermejo-Pareja
    Neurological Sciences, 2011, 32 : 309 - 311
  • [46] Utilization and safety of intramuscular interferon beta-1a in the post-marketing setting
    Hyde, R.
    Curnow, K.
    Foulds, P.
    Richman, S.
    Friend, S.
    Glick, G.
    Onigman, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 493 - 493
  • [47] Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection
    Coghe, Giancarlo
    Atzori, Laura
    Frau, Jessica
    Fenu, Giuseppe
    Lorefice, Lorena
    Marrosu, Maria Giovanna
    Cocco, Eleonora
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : 231 - 233
  • [48] Expert opinion on clinical experience with subcutaneous interferon beta-1a in multiple sclerosis patients with different disease activity profiles
    Bohlega, Saeed
    Alroughani, Raed
    Alkhawajah, Mona
    Alsaadi, Taoufik
    Daif, Abdulkader
    Elalamy, Osama R.
    Inshasi, Jihad S.
    Noori, Suzan
    Shakra, Mustafa
    Shatila, Ahmed O.
    El Boghdady, Ahmed
    Boshra, Amir
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2019, 7 (05): : 260 - 266
  • [49] Safety and Efficacy of Teriflunomide in Patients Switching from Subcutaneous Interferon Beta-1a
    Vermersch, Patrick
    Olsson, Tomas
    Czlonkowska, Anna
    Benamor, Myriam
    Truffinet, Philippe
    Purvis, Annie
    de Seze, Jerome
    NEUROLOGY, 2016, 86
  • [50] Risk of stroke in patients with multiple sclerosis treated with subcutaneous interferon beta-1a
    Sabido-Espin, M.
    Venkatesh, S.
    Aldridge, J.
    Gillett, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 1022 - 1022
12345